Clinical Trial News and Research

RSS

NIH-sponsored clinical trials examine safety, acceptability of HIV antiretroviral medicines

Two new clinical trials are examining the safety and acceptability of antiretroviral medicines administered via injection as a means of protecting against HIV infection. The studies are being funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and conducted by the NIAID-funded HIV Prevention Trials Network (HPTN).

19 Feb 2015

Weill Cornell receives NIH grant to study TB-causing bacteria

In an effort to stop tuberculosis (TB) from becoming progressively less treatable worldwide, the National Institutes of Health has awarded Weill Cornell Medical College more than $6.2 million in first-year funding to support a research collaboration among six institutions in close alliance with voluntary pharmaceutical partners.

19 Feb 2015

New clinical trial launched in South Africa to study investigational HIV vaccine regimen

A clinical trial called HVTN 100 has been launched in South Africa to study an investigational HIV vaccine regimen for safety and the immune responses it generates in study participants. This experimental vaccine regimen is based on the one tested in the U.S. Military HIV Research Program-led RV144 clinical trial in Thailand--the first study to demonstrate that a vaccine can protect people from HIV infection.

19 Feb 2015

TB Alliance announces initiation of first human trial of new TB drug candidate

TB Alliance has announced the start of the first human trial of a new tuberculosis (TB) drug candidate, designated TBA-354. It is the first new TB drug candidate to begin a Phase 1 clinical trial since 2009.

19 Feb 2015

Long-term TDF ‘promising’ in Chinese HBV patients after multiple antiviral failures

Long-term tenofovir disoproxil fumarate therapy is effective in Chinese patients with chronic hepatitis B virus infection who have relapsed after treatment with multiple nucleos(t)ide analogues, research suggests.

18 Feb 2015

PAREXEL International expands clinical trial site alliance network

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced the continued expansion of its clinical trial site alliance network, an extensive network of investigator sites and Site Management Organizations (SMOs) that enables PAREXEL to quickly access and enroll patient populations for clients' clinical trials worldwide.

From Parexel 18 Feb 2015

New class of experimental drug could help patients with bile duct cancer

Patients with bile duct cancer could be helped by a new class of experimental drug, a study has shown.

18 Feb 2015

Anticoagulant fondaparinux lowers risk of major bleeding events, death in heart attack patients

Patients who experienced a certain type of heart attack who received the anticoagulant fondaparinux had a lower risk of major bleeding events and death both in the hospital and after six months compared to patients who received low-molecular-weight heparin (LMWH), although both groups had similar rates of subsequent heart attack or stroke, according to a study in the February 17 issue of JAMA.

18 Feb 2015

Second-line bosutinib well tolerated by Japanese patients

Phase I/II clinical trial data support the use of bosutinib as second- or third-line tyrosine kinase inhibitor therapy in Japanese patients with Philadelphia chromosome-positive chronic myeloid leukaemia.

17 Feb 2015

Cabazitaxel therapy may be more effective in treating prostate cancer

Prostate cancer is the second leading cause of cancer for men in the United States. Only one class of chemotherapy called taxanes is effective against the disease.

17 Feb 2015

CryoLife's revenues increase 5% to $37.2M in fourth quarter 2014

CryoLife, Inc., a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today its results for the fourth quarter and full year of 2014.

17 Feb 2015

UMHS opens Massey Emergency Critical Care Center

They come from highway accident scenes and nursing home beds, from factories and farm fields, from suburban homes, downtown sidewalks and small community hospitals.

16 Feb 2015

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira, Inc., a world leader in the development of biosimilar therapies, today announced the launch of the first biosimilar monoclonal antibody (mAb), Inflectra (infliximab), in major European markets.

16 Feb 2015

Henry Ford physicians suction cancerous tumor from vein in metastatic kidney cancer patient

Physicians at Henry Ford Hospital successfully suctioned a cancerous tumor from a major vein in a patient with metastatic kidney cancer, clearing the way for him to undergo a minimally-invasive kidney removal. This allowed him to participate in a clinical trial using genetic material from his tumor to produce a vaccine to help fight his metastatic disease.

16 Feb 2015

TSRI scientists discover novel mechanism involved in Alzheimer's, Parkinson's and ALS

Scientists from the Florida campus of The Scripps Research Institute have for the first time discovered a killing mechanism that could underpin a range of the most intractable neurodegenerative diseases such as Alzheimer's, Parkinson's and ALS.

16 Feb 2015

Short-term cognitive behavioral therapy reduces suicide attempts among at-risk soldiers

Short-term cognitive behavioral therapy dramatically reduces suicide attempts among at-risk military personnel, according to findings from a research study that included investigators from The University of Texas Health Science Center at San Antonio.

16 Feb 2015

Novartis receives priority review status from FDA for heart failure medicine LCZ696

Novartis announced today that the US Food and Drug Administration has granted priority review for LCZ696, an investigational medicine for the treatment of heart failure with reduced ejection fraction (HFrEF). The designation is intended to accelerate the review of therapies that offer a significant improvement in the safety or effectiveness of the treatment, prevention or diagnosis of a serious condition.

16 Feb 2015

Cervarix effective against other common cancer-causing HPVs

According to a multinational clinical trial involving nearly 20,000 young women, the human papilloma virus vaccine, Cervarix, not only has the potential to prevent cervical cancer, but was effective against other common cancer-causing human papillomaviruses, aside from just the two HPV types, 16 and 18, which are responsible for about 70 percent of all cases.

15 Feb 2015

Pelvalon receives FDA approval to market Eclipse System for improving bowel control in women

Pelvalon announced today that the U.S. Food and Drug Administration has granted the company's de novo request to market the Eclipse System, the first vaginal insert designed to provide bowel control, in the United States. Loss of bowel control, also known as fecal incontinence, is a condition that affects over 20 million women in the U.S.

14 Feb 2015

$Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC$

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).

13 Feb 2015

Clinical Trial News and Research

NIH-sponsored clinical trials examine safety, acceptability of HIV antiretroviral medicines

Weill Cornell receives NIH grant to study TB-causing bacteria

New clinical trial launched in South Africa to study investigational HIV vaccine regimen

TB Alliance announces initiation of first human trial of new TB drug candidate

Long-term TDF ‘promising’ in Chinese HBV patients after multiple antiviral failures

PAREXEL International expands clinical trial site alliance network

New class of experimental drug could help patients with bile duct cancer

Anticoagulant fondaparinux lowers risk of major bleeding events, death in heart attack patients

Second-line bosutinib well tolerated by Japanese patients

Cabazitaxel therapy may be more effective in treating prostate cancer

CryoLife's revenues increase 5% to $37.2M in fourth quarter 2014

UMHS opens Massey Emergency Critical Care Center

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Henry Ford physicians suction cancerous tumor from vein in metastatic kidney cancer patient

TSRI scientists discover novel mechanism involved in Alzheimer's, Parkinson's and ALS

Short-term cognitive behavioral therapy reduces suicide attempts among at-risk soldiers

Novartis receives priority review status from FDA for heart failure medicine LCZ696

Cervarix effective against other common cancer-causing HPVs

Pelvalon receives FDA approval to market Eclipse System for improving bowel control in women

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer